Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Increase in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 493,245 shares, an increase of 2,767.7% from the May 31st total of 17,200 shares. Based on an average daily trading volume, of 5,161,875 shares, the short-interest ratio is currently 0.1 days. Currently, 0.6% of the company’s stock are short sold.

Indaptus Therapeutics Stock Down 8.2%

Indaptus Therapeutics stock traded down $0.29 during midday trading on Thursday, reaching $3.26. The company’s stock had a trading volume of 92,782 shares, compared to its average volume of 2,953,706. The company has a market cap of $369.16 million, a P/E ratio of -0.21 and a beta of 1.25. The business has a 50-day simple moving average of $2.62 and a 200-day simple moving average of $2.34. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $13.44.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.87) by $1.64.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Indaptus Therapeutics has a consensus rating of “Sell”.

Hedge Funds Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.